A changing landscape in castration-resistant prostate cancer treatment

A. Felici, M. S. Pino, Paolo Carlini

Research output: Contribution to journalArticle

Abstract

Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20% of men with PC present with metastatic disease at diagnosis, while 20-30% of patients diagnosed with localized disease will eventually develop metastases. Although most respond to initial androgen- deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In 2004 the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have now led to an unprecedented number of new drug approvals within the past years, provid- ing many new treatment options for patients with metastatic CRPC. Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel- T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. The data supporting the approval of each of these agents are described in this review, as are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of novel treatments and strategies.

Original languageEnglish
Article numberArticle 85
JournalFrontiers in Endocrinology
Volume3
Issue numberJUL
DOIs
Publication statusPublished - 2012

Fingerprint

Castration
Prostatic Neoplasms
Drug Approval
docetaxel
Androgens
Therapeutics
Western World
Second Primary Neoplasms
Prednisone
Microtubules
Cause of Death
Clinical Trials
Neoplasm Metastasis
Bone and Bones
Food
Pharmaceutical Preparations
Neoplasms

Keywords

  • Abiraterone
  • Cabazitaxel
  • Castration-resistance
  • Denosumab
  • Prostate cancer
  • Sipuleucel-T

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

A changing landscape in castration-resistant prostate cancer treatment. / Felici, A.; Pino, M. S.; Carlini, Paolo.

In: Frontiers in Endocrinology, Vol. 3, No. JUL, Article 85, 2012.

Research output: Contribution to journalArticle

@article{fc513d4d820444a6ae4186efc688ce64,
title = "A changing landscape in castration-resistant prostate cancer treatment",
abstract = "Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20{\%} of men with PC present with metastatic disease at diagnosis, while 20-30{\%} of patients diagnosed with localized disease will eventually develop metastases. Although most respond to initial androgen- deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In 2004 the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have now led to an unprecedented number of new drug approvals within the past years, provid- ing many new treatment options for patients with metastatic CRPC. Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel- T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. The data supporting the approval of each of these agents are described in this review, as are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of novel treatments and strategies.",
keywords = "Abiraterone, Cabazitaxel, Castration-resistance, Denosumab, Prostate cancer, Sipuleucel-T",
author = "A. Felici and Pino, {M. S.} and Paolo Carlini",
year = "2012",
doi = "10.3389/fendo.2012.00085",
language = "English",
volume = "3",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - A changing landscape in castration-resistant prostate cancer treatment

AU - Felici, A.

AU - Pino, M. S.

AU - Carlini, Paolo

PY - 2012

Y1 - 2012

N2 - Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20% of men with PC present with metastatic disease at diagnosis, while 20-30% of patients diagnosed with localized disease will eventually develop metastases. Although most respond to initial androgen- deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In 2004 the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have now led to an unprecedented number of new drug approvals within the past years, provid- ing many new treatment options for patients with metastatic CRPC. Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel- T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. The data supporting the approval of each of these agents are described in this review, as are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of novel treatments and strategies.

AB - Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20% of men with PC present with metastatic disease at diagnosis, while 20-30% of patients diagnosed with localized disease will eventually develop metastases. Although most respond to initial androgen- deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In 2004 the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have now led to an unprecedented number of new drug approvals within the past years, provid- ing many new treatment options for patients with metastatic CRPC. Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel- T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. The data supporting the approval of each of these agents are described in this review, as are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of novel treatments and strategies.

KW - Abiraterone

KW - Cabazitaxel

KW - Castration-resistance

KW - Denosumab

KW - Prostate cancer

KW - Sipuleucel-T

UR - http://www.scopus.com/inward/record.url?scp=84874425541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874425541&partnerID=8YFLogxK

U2 - 10.3389/fendo.2012.00085

DO - 10.3389/fendo.2012.00085

M3 - Article

C2 - 22826702

AN - SCOPUS:84874425541

VL - 3

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - JUL

M1 - Article 85

ER -